9-13-2016 – Press Release from: TMR – Research Reports
Degradable and bioabsorbable osteosynthesis devices have reached a point in their commercialization cycle where they now carry the capability to transform the future of the global osteosynthesis devices market as a whole. Although the global osteosynthesis devices market is currently dominated by devices made from non-degradable materials—mainly metals—the future clearly belongs to degradable materials. This also explains why companies have trained their focus on developing innovative materials that can heal fractures and be gradually absorbed by the body. Besides the physical benefits that come along with degradable osteosynthesis devices, the economic benefits are also making them an attractive option – mainly because they eliminate the need for a second implant removal surgery.
- DePuy Synthes alone commanded over 48.6% of the osteosynthesis devices market in 2014. The company’s formidable stake in the market was a result of DePuy (Johnson & Johnson company) joining forces with Synthes to gain a wider presence in the market.
- The next leading player in the osteosynthesis devices market as of 2014 was Stryker Corporation, boasting nearly 24% of market revenues. The company has an expansive range of products, including but not limited to hip fixation devices and intramedullary nail devices.
- Nearly 11.6% of the osteosynthesis devices market, in 2014, was held by Zimmer Biomet. Although the company’s product portfolio comprises numerous non-degradable osteosynthesis devices, it is focusing on developing newer materials and devices that are safety-evaluated by leading agencies.